Calliditas Therapeutics Receives Accelerated Approval of TARPEYO™ to Reduce Proteinuria in IgA Nephropathy
Calliditas Therapeutics AB (NASDAQ: CALT) shares jumped about 28% Thursday after the Company announced that the US Food and Drug Administration (FDA) has approved TARPEYO (budesonide) delayed release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN)...